Lipid Nanoparticles (LNP) Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2022 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Lipid Nanoparticles (LNP) Market: By Type (mRNA-lipid Nanoparticle, siRNA-lipid Nanoparticle, and Others), by Application (Vaccines & Drugs and Scientific Research), and by Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Lipid Nanoparticles (LNP) Market size was valued at USD 627.9 million in 2021 and is poised to grow at a significant CAGR of 7.5% over 2022–2028. Nanoparticles have received interest recently because of their potential role in efficient medication delivery. LNPs are now widely recognized in the pharmaceutical and biotechnology sectors as a cutting-edge, commercially successful delivery system enabling the unheard-of commercialization of gene treatments. As a result, LNPs have ushered in a new era of medicine that allows for the effective treatment or cure of genetic illnesses and the production of vaccines within the body rather than through the purification of non-infectious viruses. For the creation of therapeutic products for protein replacement therapy, preventive or curative vaccinations, and gene editing, LNP-based formulations provide significant prospects. LNP-based formulations are increasingly being considered for use across a variety of other application areas, including anticancer agents and antibiotics, peptide and protein-based synthetic vaccines, ligand targeted formulations, and imaging contrast agents, in addition to RNA, DNA, and siRNA-based therapeutics. LNPs are anticipated to facilitate the creation of ever more sophisticated nanomedicines during the next ten years. Examples include the design of synthetic vaccines, immunotherapies, and drug combination products when LNP-based formulations are necessary to guarantee the co-presentation of various components into the target cell. Personalized or custom formulations that can enable results like the insertion of tumor-associated neoantigens into mRNA vaccines are another opportunity that can be achieved by combining LNPs with tissue sequencing and other valuable technologies.

Recent Market Developments:

In February 2021, Merck announced the extension of its strategic partnership with BioNTech to accelerate the supply of urgently needed lipids and increase the quantities to be delivered in 2021. The lipids were used for the production of the Pfizer-BioNTech Covid-19 vaccine.

Lipid Nanoparticles (LNP) Market

MARKET SUMMARY
-
7.5%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 7.5%
  • Largest Market– Asia Pacific
  • Fastest Growing Market– North America

Lipid Nanoparticles (LNP) Market

  • The report on global lipid nanoparticles (lnp) market gives historical, current and future market sizes (US$ Mn) on the basis of type, application, and geography.
  • The lipid nanoparticles (lnp) market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Merck KGaA
  • Genevant Sciences
  • Exelead
  • Avanti Polar Lipids
  • Nippon Fine Chemical
Lipid Nanoparticles (LNP) Market Dynamics

Due to their use as the ideal delivery method for various messenger RNA (mRNA)-based vaccination candidates being developed for the prevention of COVID-19, lipid nanoparticles (LNPs) have recently attracted much attention. Over approximately 30 years of commercial use, lipid nanoparticles’ capacity to encapsulate genetic material, including mRNA, and a variety of other biologically active substances, for regulated delivery to a target cell or organ site has been clinically demonstrated. LNPs have a long history of successful use in clinical settings and can be quickly created and scaled up into a final product, making them the de facto standard for gene- and cell-based therapies and other nanomedicines. Regulatory agencies and organizations and high production and R&D costs may restraints the market growth.


North-America Got Significant Share

Lipid Nanoparticles (LNP) Market

The Lipid Nanoparticles (LNP) market in North America are likely to hold a significant revenue share in 2021, and, in the following years, it is predicted to increase rapidly. The growth of mRNA vaccines and therapeutics is anticipated to be driven by an increase in the use of advanced vaccines and therapeutics due to increasing disposable income and an increase in the prevalence of chronic and infectious diseases. Rising interest due to the increased prevalence of cancer and chronic diseases, as well as the growing emphasis on physical wellness, and medicines, are expected to increase LNP sales in the area. Europe is anticipated to be one of the important markets for lipid nanoparticles. Robust healthcare infrastructure and increased biopharmaceutical companies in the area are some of the primary drivers of the European lipid nanoparticles market's expansion. The European lipid nanoparticle demand is driven by increased genetic abnormalities, cancer prevalence, and vaccine awareness.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The Lipid Nanoparticles (LNP) Market report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Lipid Nanoparticles (LNP) Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The lipid nanoparticles (lnp) market is projected to expand at a CAGR of 7.5% during the forecast period

Precision NanoSystems, Evonik, Merck KGaA, Genevant Sciences, Exelead

North America is the fastest-growing region for lipid nanoparticles (lnp) market


Report

Company Profile

  • Precision NanoSystems
  • Evonik
  • Merck KGaA
  • Genevant Sciences
  • Exelead
  • Avanti Polar Lipids
  • Nippon Fine Chemical
  • Lipoid

Description

Lipid Nanoparticles (LNP) Market size was valued at USD 627.9 million in 2021 and is poised to grow at a significant CAGR of 7.5% over 2022–2028. Nanoparticles have received interest recently because of their potential role in efficient medication delivery. LNPs are now widely recognized in the pharmaceutical and biotechnology sectors as a cutting-edge, commercially successful delivery system enabling the unheard-of commercialization of gene treatments. As a result, LNPs have ushered in a new era of medicine that allows for the effective treatment or cure of genetic illnesses and the production of vaccines within the body rather than through the purification of non-infectious viruses. For the creation of therapeutic products for protein replacement therapy, preventive or curative vaccinations, and gene editing, LNP-based formulations provide significant prospects. LNP-based formulations are increasingly being considered for use across a variety of other application areas, including anticancer agents and antibiotics, peptide and protein-based synthetic vaccines, ligand targeted formulations, and imaging contrast agents, in addition to RNA, DNA, and siRNA-based therapeutics. LNPs are anticipated to facilitate the creation of ever more sophisticated nanomedicines during the next ten years. Examples include the design of synthetic vaccines, immunotherapies, and drug combination products when LNP-based formulations are necessary to guarantee the co-presentation of various components into the target cell. Personalized or custom formulations that can enable results like the insertion of tumor-associated neoantigens into mRNA vaccines are another opportunity that can be achieved by combining LNPs with tissue sequencing and other valuable technologies.

Recent Market Developments:

In February 2021, Merck announced the extension of its strategic partnership with BioNTech to accelerate the supply of urgently needed lipids and increase the quantities to be delivered in 2021. The lipids were used for the production of the Pfizer-BioNTech Covid-19 vaccine.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX